The Rhythm | Issue 12
Issue 12 | Week of 22 June 2026
No major cardiology congress fell this week, and the most consequential evidence again arrived through journal publication. A single thread ran through it: cardiology is increasingly judged not on how a therapy performs at one or two years, but on whether its advantage survives a decade and whether acting earlier compounds into a lifetime of benefit.
Cardiology Intelligence Briefing: the long game arrives
This week's papers kept returning to the same question: time. Not simply whether an intervention works early, but whether the decision still looks right years later.
The clearest test came from structural heart disease, where ten-year follow-up showed that not all transcatheter valve durability signals can be treated alike. An older balloon-expandable transcatheter valve carried higher long-term mortality and more reintervention than surgery, while a later-generation SAPIEN 3 valve matched surgery in a propensity-matched comparison.1 For transcatheter valves, five-year reassurance is no longer enough. Durability has become the currency of valve choice.
The same long horizon framed coronary intervention. A sirolimus-eluting balloon strategy for de novo lesions met its one-year non-inferiority bar in the intention-to-treat analysis, but the stricter per-protocol analysis did not confirm it, and repeat revascularisation was more frequent.2 The concept is attractive: treat the lesion, leave less permanent metal behind, and hope that fewer late device-related events follow. But that promise belongs to the five-year data, not the one-year headline.
Elsewhere, the week showed the value of measuring benefit over time rather than at a single point. In obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten outperformed metoprolol across a wider exercise-physiology profile, moving the comparison beyond symptom control and toward objective functional capacity.3 In prevention, the cumulative argument was even clearer. In familial hypercholesterolaemia, starting cholesterol-lowering therapy in childhood or adolescence was associated with lower lifetime low-density lipoprotein cholesterol (LDL-C) burden and far fewer early cardiovascular events than treatment delayed until adulthood.4 In established atherosclerotic disease, earlier rather than delayed evolocumab was associated with fewer complex coronary revascularisations over long-term follow-up.5
Taken together, the week argued that the important question is no longer only whether a therapy works, but how early its benefit starts and how long that benefit lasts. Early action, sustained measurement, and durability are becoming the real tests of value. In cardiology, the strongest evidence is not the result that looks best at one year, but the one that still holds up years later.
